Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Cancer|February 29, 2024
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancerAaron C Tan, Gillianne G Y Lai, Stephanie P L Saw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2020
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLCAaron C Tan, Amanda O L Seet, Gillianne G Y Lai, et al.
Frontiers in Oncology|August 2, 2021
Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast CancerSay Li Kong, Xingliang Liu, Swee Jin Tan, et al.
Plos One|May 9, 2015
Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAmit Jain, Cindy Lim, Eugene MingJin Gan, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2019
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysisAaron C Tan, Gillianne G Y Lai, Gek San Tan, et al.
JTO Clinical and Research Reports|November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLCGillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2019
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerGillianne G Y Lai, Tse Hui Lim, John Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic OpportunitiesKhi Pin Chua, Yvonne H F Teng, Aaron C Tan, et al.
Nature Medicine|March 20, 2012
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerKing Pan Ng, Axel M Hillmer, Charles T H Chuah, et al.
Pageof 7